MK2 Kinase Inhibitor Synthesis Yield via Streamlined Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing MK2 kinase inhibitors face challenges in yield and efficiency due to the use of unstable intermediates and oxidizing agents, with existing syntheses involving complex steps and low overall yields.
Innovation Solution
The synthesis of MK2 kinase inhibitors is improved by optimizing the production of intermediate compounds, such as compound P, through streamlined processes that eliminate unstable intermediates and oxidizing agents, resulting in higher yields and improved physical and chemical properties, specifically focusing on the synthesis of compound I-a with a yield of at least 37% and overall yield of at least 22.7%.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthesis methods are used, then MK2 kinase inhibitors can be produced, but the yield is low and the process is complex due to unstable intermediates and oxidizing agents
Solution Approach 1:
The patent removes unstable intermediates and oxidizing agents from the synthesis pathway. Specifically, the method eliminates the need for oxidizing agents by using a reductive amination approach, and avoids isolating unstable intermediates by proceeding directly to the next transformation step, thereby simplifying the overall synthesis process and improving yield
Solution Approach 2:
The synthesis is divided into discrete, optimized steps with specific reagents and conditions for each transformation. The multi-step synthesis is segmented into manageable stages including condensation, cyclization, and substitution reactions, each with controlled parameters to maximize yield and minimize complexity
2Quantity of substance
If existing synthesis methods are used, then MK2 kinase inhibitors can be produced, but the overall yield is low (less than 22.7%)
Solution Approach 1:
The synthesis method employs continuous transformation where reaction products are directly carried forward to the next step without isolation or purification in between. This continuous flow approach minimizes material loss and reduces the overall synthesis time while maintaining high yield (at least 22.7%)
Solution Approach 2:
Protecting groups are strategically installed in advance to prevent unwanted side reactions during subsequent steps. The preliminary protection of sensitive functional groups allows for more efficient subsequent transformations and reduces the need for repeated purification steps, thereby improving overall yield and reducing time
Data Source
AI summary
The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.